Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Overall Study	STARTED	Filgotinib 200 mg	477
Overall Study	STARTED	Filgotinib 100 mg	480
Overall Study	STARTED	Adalimumab	325
Overall Study	STARTED	Placebo to Filgotinib 200 mg	190
Overall Study	STARTED	Placebo to Filgotinib 100 mg	191
Overall Study	STARTED	Placebo Never Received Filgotinib	96
Overall Study	COMPLETED	Filgotinib 200 mg	424
Overall Study	COMPLETED	Filgotinib 100 mg	422
Overall Study	COMPLETED	Adalimumab	281
Overall Study	COMPLETED	Placebo to Filgotinib 200 mg	181
Overall Study	COMPLETED	Placebo to Filgotinib 100 mg	185
Overall Study	COMPLETED	Placebo Never Received Filgotinib	24
Overall Study	NOT COMPLETED	Filgotinib 200 mg	53
Overall Study	NOT COMPLETED	Filgotinib 100 mg	58
Overall Study	NOT COMPLETED	Adalimumab	44
Overall Study	NOT COMPLETED	Placebo to Filgotinib 200 mg	9
Overall Study	NOT COMPLETED	Placebo to Filgotinib 100 mg	6
Overall Study	NOT COMPLETED	Placebo Never Received Filgotinib	72

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02889796/flow